Jeito Capital announces significant participation in $187 million Series A financing for Callio Therapeutics to advance innovative multi-payload ADC programs designed to maximize therapeutic benefit for cancer patients
Callio Therapeutics is a biotechnology company developing multi-payload ADCs with technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience
Investment will contribute to achieve clinical proof-of-concept for
Callio's HER-2-targeted dual-payload ADC and a second undisclosed ADC program
Jeito's investment reinforces its commitment to cutting-edge oncology innovations addressing treatment resistance and improving patient outcomes
Paris, March 3rd 2025 – Jeito Capital ('Jeito'), a global leading independent Private Equity fund dedicated to biopharma, announced today its significant participation in the $187 million (€180.2 million1) Series A financing round in Callio Therapeutics ('Callio'), a newly launched biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy.
Callio Therapeutics was founded by Frazier Life Sciences to develop next-generation multi-payload antibody-drug conjugates (ADCs) based on technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience. The company is led by co-founder and CEO Piers Ingram, PhD, alongside a founding management team with deep expertise in ADC development bringing experience from leading biotechnology and biopharmaceutical companies (including Hummingbird Bioscience, ProfoundBio, Silverback Therapeutics, SeaGen, Medarex, and Genentech).
The $187 million Series A financing was led by Frazier Life Sciences with significant participation from Jeito alongside an investment syndicate including Novo Holdings A/S Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI. The strength of this syndicate underscores the broad confidence in Callio's innovative ADC platform and its potential to reshape cancer therapy.
Callio Therapeutics will use the proceeds from the Series A financing to achieve clinical proof-of-concept for its HER2-targeted dual-payload ADC and a second undisclosed ADC program, all designed to maximize therapeutic benefit for cancer patients by overcoming the limitations of single-payload therapies. By enabling the targeted delivery of rational drug combinations to tumor cells, Callio's approach has the potential to significantly enhance efficacy and address resistance mechanisms.
Rachel Mears, Partner at Jeito will join Callio's Board of Director as Board member.
Through this investment, Jeito reinforces its commitment to supporting transformative oncology innovations that address key resistance mechanisms in cancer treatment. Callio's differentiated multi-payload ADC platform aligns with Jeito's investment thesis of backing high-potential biopharma companies developing next-generation therapies with the potential for global leadership.
Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital said: ' We are pleased to support Callio Therapeutics as it advances its differentiated multi-payload ADC platform to address some of the biggest challenges in oncology. As long-standing investors in this therapeutic area, we recognize the quality and potential of Callio's approach to overcome resistance mechanisms and improve outcomes for patients with hard-to-treat cancers. At Jeito, we believe that strategic collaboration and bold innovation are key to accelerating the next generation of targeted therapies, and we look forward to working alongside the Callio team to bring these advances to patients in need. '
Rachel Mears, Parner at Jeito Capital added: ' Callio is a highly innovative company that benefits from an experienced management team and deep expertise in oncology, where new therapies remain highly needed for those suffering from various forms of cancer. We look forward to collaborating with Callio's team through our collective knowledge and expertise in both ADC and oncology with the ambition to go faster to patients with high unmet needs. '
Piers Ingram, PhD, co-founder and Chief Executive Officer of Callio Therapeutics concluded: ' We are delighted to be launching Callio Therapeutics with this very strong syndicate of investors. Multi-payload ADCs have the potential to enable the targeted delivery of rational drug combinations to cancer cells, and may provide significantly enhanced efficacy. This new generation of ADC therapies may meaningfully improve outcomes for patients.'
About Jeito Capital
Jeito Capital is a global leading Private Equity fund with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients' access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States.
For more information, please visit www.jeito.life or follow us on LinkedIn or X.
About Callio Therapeutics
Headquartered in Seattle and Singapore, Callio Therapeutics is focused on realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes. The company is developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies that enable targeted delivery of multi agents to tumor cells to maximize therapeutic benefit. Callio Therapeutics' lead program is a HER2-targeted dual-payload ADC. Callio Therapeutics was created by Frazier Life Sciences, a longstanding investment firm focused on innovative therapeutics, based on ADC technology and programs exclusively in-licensed from Hummingbird Bioscience. For more information , please visit www.calliotx.com and follow Callio Therapeutics on LinkedIn.
Contacts:
Jeito Capital
Rafaèle Tordjman, Founder & CEO
Jessica Fadel, EA
Tel: +33 6 33 44 25 47
Maior
Stéphanie Elbaz – Tel: +33 6 46 05 08 07
ICR Healthcare
Mary-Jane Elliott / Davide Salvi / Kris Lam
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Green Hydrogen Production Group Closes on Major Investment
A California-based hydrogen production group said it has completed a funding round in support of the company's first 100-kilotonne carbon dioxide removal (CDR) commercial facility. Equatic, which is considered a pioneering company in combined carbon dioxide removal and green hydrogen production, on August 11 announced the successful closure of its Series A round, with Catalytic Capital for Climate and Health (C3H) leading an $11.6-million investment. C3H is a catalytic vehicle by Temasek Trust, along with Kibo Invest, a Singapore-based private investment office with a focus on climate technology. The funding round, with participation from a consortium of global investors, will accelerate the engineering scale-up and commercialization of Equatic's patented seawater electrolysis technology. This substantial capital infusion will support the ongoing engineering of Equatic's CDR commercial facility, alongside further commercialization, manufacturing, and technological development. Equatic's proprietary technology is designed to capture atmospheric carbon dioxide and produce green hydrogen in a single, scalable process, advancing two critical net-zero pathways. 'This investment marks a pivotal moment for Equatic, enabling us to significantly scale our production capabilities and accelerate our mission to deliver durable carbon removal at scale,' said Gaurav N. Sant, founder and chief technology officer for Equatic. 'The Temasek Trust ecosystem has been a foundational partner to Equatic, from early-stage philanthropic backing from Temasek Foundation to catalytic investment through C3H. We welcome Kibo Invest as co-lead and recognize their commitment to invest in companies that are revolutionizing industries and addressing urgent climate challenges.' 'Truly innovative carbon management technologies are needed to mitigate climate change before the consequences become irreversible,' said Lord John Browne, chairman of Equatic's advisory board. Browne also is founder and chairman at BeyondNetZero, and the former CEO of British Petroleum. 'By removing carbon dioxide and simultaneously generating green hydrogen, Equatic's solution provides unique advantages in terms of cost and scalability.' Ryan Tan, head of C3H, said, 'Equatic's technology and approach exemplify the type of bold and scalable innovation that aligns with C3H's mandate. We are delighted to support Equatic's goal in advancing promising climate mitigation solutions that offer permanent, durable carbon removal with green hydrogen production for scalable, tangible impact and commercial benefit.' 'Equatic represents an exciting opportunity to scale deep-tech innovation that addresses two critical needs: decarbonisation and clean energy. As an investor focused on climate solutions, we are proud to partner with C3H and Equatic to help bring this breakthrough technology to commercial scale,' said James Marshall, CEO of Kibo Invest. Equatic's Technology Since commencing operations in 2023, the Equatic technology has been successfully deployed at two pilot plants in Los Angeles and Singapore. The company is now expanding its operations with a demonstration plant in Singapore, known as Equatic-1, and a commercial-scale plant in Canada. In May 2024, Equatic was recognized as a CDR Purchase Prize semifinalist by the U.S. Department of Energy, acknowledging its high-quality, permanent carbon credits and rigorous Monitoring, Reporting, and Verification (MRV) practices. In September 2024, Equatic announced a significant climate breakthrough with the U.S. manufacture of oxygen-selective anodes, which unlock scalable hydrogen production through direct seawater electrolysis. That same month, Equatic was named a finalist for The Earthshot Prize, a prestigious international recognition for groundbreaking solutions to repair the planet. Equatic's commitment to high-integrity carbon removal is underscored by its adoption of an ISO-14064 standard for MRV, first published by Equatic in May 2023. Subsequently, this standard was validated by two leading carbon removal registries, Isometric and making Equatic one of the only marine companies capable of issuing high-quality CDR credits under either registry, with full transparency and auditability. Buyers of Equatic's CDR credits include Boeing, a leading global aerospace company and other large industrial companies committed to market-based mechanisms for decarbonization. —POWER edited this content, which was contained in a press release from Equatic. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
'Lots of turbulence': Air Canada flyers describe cancellation, rebooking chaos amid strike
Travellers in Canada and abroad scrambled to secure flights on Sunday after striking Air Canada flight attendants defied a federal back-to-work order, abruptly halting the airline's plans to resume operations. Lila Rousseaux, who was scheduled to fly home with her family from Zurich to Toronto on Sunday, told CBC News she spent all of Saturday glued to her phone for news about whether her flight would be cancelled. At 12:30 a.m. on Sunday, she was informed it was. "I spent one and a half hours on the phone with the agent ... lots of turbulence," Rousseaux said. "There was a lot of inflexibility in terms of what can be done," she said, adding that her suggestions to take a train to Amsterdam to catch a plane or fly directly to the U.S. before driving across the border were rebuffed by the agent. WATCH | Lila Rousseaux describes 'turbulence' of rebooking flight: Rousseaux said she finally booked an "awful" overnight flight to Atlanta, lamenting that she is no longer being seated with children. "The distress in my family is very acute," she said. Ottawa moved to intervene in the labour dispute on Saturday, less than 12 hours after the strike and lockout took effect, with federal Jobs Minister Patty Hajdu saying she was invoking Section 107 of the Canada Labour Code to ask the Canada Industrial Relations Board (CIRB) to send the two sides to binding arbitration and to order the airline and its flight attendants back to work in the meantime. The Montreal-based airline subsequently announced early Sunday that it planned to resume flights in the evening, but just hours later, the union representing more than 10,000 flight attendants said in a statement that members would remain on strike — scuttling those plans and prompting Air Canada to cancel some 240 flights. WATCH | Hundreds of flight attendants picket at Vancouver airport: At Vancouver International Airport, passengers stood in long lines to get the latest updates on their delayed and cancelled flights, as workers outside demonstrated with signs reading, "Unpaid work won't fly." Chi Ehis told The Canadian Press she is having to pay an extra $2,000 to meet her family in Florida for a vacation after her flight was cancelled Sunday morning. Instead of flying straight from Vancouver, she is now taking a bus to Seattle before catching another, pricier flight. "I can't scream. I have to just figure out what to do," Ehis said, adding her plane ticket cost $1,500. WATCH | Tips for Air Canada passengers from travel influencer Moxey Munch: In Toronto, Khalid Muhammadi told CBC News he flew in from Dubai en route to Edmonton but is now stuck at Pearson International Airport. "WestJet is asking eight grand; what am I supposed to do?" he said. Muhammadi voiced frustrations with the federal government for not resolving the labour dispute. "You knew a strike was coming ... do your job." Air Canada has said passengers whose flights are cancelled will be offered a full refund or the opportunity to change their travel plans without a fee. However, it said that under Canada's airline passenger protection regulations, customers are not eligible for compensation for expenses incurred during travel delays deemed outside the airline's control. "Customers in Canada are not eligible for compensation for delayed or cancelled flights, meals, hotels or other incidental expenses for situations outside the carrier's control, such as a labour disruption," the airline said. Air Canada said in a news release that its flights would resume Monday evening, although a notice on its booking page said all Air Canada and Air Canada Rouge flights were cancelled until further notice. Solve the daily Crossword
Bloomberg
an hour ago
- Bloomberg
Thoma Bravo Is Said to Be in Talks to Buy Software Firm Dayforce
Thoma Bravo is in talks to acquire human resources management software provider Dayforce Inc., according to people familiar with the matter. The buyout firm is working on a take- private of Minneapolis-based Dayforce that could be announced as soon as the coming weeks, the people said, asking not to be identified as the matter is private.
